Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse

  title={Abuse liability and safety of oral lisdexamfetamine dimesylate in individuals with a history of stimulant abuse},
  author={Donald R. Jasinski and Suma Krishnan},
  journal={Journal of Psychopharmacology},
  pages={419 - 427}
Abstract Lisdexamfetamine dimesylate (LDX) is the first prodrug stimulant and is indicated for the treatment of attention-deficit/hyperactivity disorder. A single-centre, double-blind, randomised, placebo-controlled, 6-period crossover study evaluated the abuse potential of single oral doses of 50, 100 (equivalent to 40 mg d-amphetamine), and 150 mg LDX, 40 mg d-amphetamine and 200 mg diethylpropion in 36 individuals with a history of stimulant abuse. On the primary abuse liability measure… 

Figures and Tables from this paper

Lisdexamfetamine Dimesylate: Prodrug Delivery, Amphetamine Exposure and Duration of Efficacy
Drug-liking scores for LDX are lower than for an equivalent dose of IR d-amphetamine, which may result from the reduced euphorigenic potential associated with its pharmacokinetic profile.
Intranasal versus Oral Administration of Lisdexamfetamine Dimesylate
IN administration of lisdexamfetamine dimesylate resulted in d-amphetamine plasma concentrations and systemic exposure to d- methamphetamine comparable to those seen with PO administration and both PO and IN demonstrated a tolerability profile similar to that of other long-acting stimulants.
The use of lisdexamfetamine dimesylate for the treatment of ADHD and other psychiatric disorders
The most important pharmacological aspects of LDX as well as data on the efficacy, tolerability and safety of this long-acting amphetamine prodrug collected from clinical studies recently published in the literature are covered.
A Systematic Review of the Safety of Lisdexamfetamine Dimesylate
Post-marketing survey data suggest that the rate of non-medical use of LDX was lower than that for short- acting stimulants and lower than or equivalent to long-acting stimulant formulations.
Pharmacokinetics and Pharmacodynamics of Lisdexamfetamine Compared with D-Amphetamine in Healthy Subjects
The pharmacokinetics and pharmacodynamics of lisdexamfetamine are similar to D-amphetamine administered 1h later, and are likely associated with a similar risk of oral abuse as D- methamphetamine.
Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study
LDX at a dose of up to 250 mg/day was safe and well tolerated by study participants, warranting larger trials as a pharmacotherapy for MA dependence.
Lisdexamfetamine Dimesylate: A Prodrug Stimulant for the Treatment of ADHD in Children and Adults
This review of LDX presents the efficacy, safety, and pharmacokinetic profile of this novel stimulant medication, and is intended to help clinicians understand its role in treating children and adults with ADHD.
Lisdexamfetamine: Stimulant Prodrug for ADHD in Children and Adults:
The d-amphetamine levels from LDX are more consistent than that from extended release mixed amphetamine salts and the rate limited enzyme mediated step underlies the consistent, predictable levels throughout the day and limits its potential for misuse.


Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD.
The characteristics of clinical use (low doses administered orally and titrated for therapeutic effects) constrain methylphenidate's abuse.
Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man
This study suggests that it is unlikely that these central actions in man are a consequence of the release of norepinephrine in the brain, and suggests that these five agents share a common mode of central action.
History and current perspectives on the use of drug formulations to decrease the abuse of prescription drugs.
Attention-deficit hyperactivity disorder
The Texas Children's Medication Algorithm Project: revision of the algorithm for pharmacotherapy of attention-deficit/hyperactivity disorder.
Medication algorithms for ADHD can be modified to keep abreast of developments in the field and may be a useful approach to guide the treatment of ADHD in children.
Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder.
This guideline, the second in a set of policies on this condition, is intended for use by clinicians working in primary care settings and contains the following recommendations for the treatment of a child diagnosed with ADHD.
Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder.
  • S. Pliszka
  • Psychology, Medicine
    Journal of the American Academy of Child and Adolescent Psychiatry
  • 2007
This practice parameter describes the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder (ADHD) based on the current scientific evidence and clinical